靶向α3β4烟碱型受体改善饮食诱导肥胖小鼠的外周胰岛素敏感性
在饮食诱导肥胖(DIO)野生型(WT)和Chrnb4敲除(KO)小鼠中,单次或每日皮下注射α3β4烟碱型乙酰胆碱受体激动剂DMPP(10 mg/kg体重)最长14天。急性DMPP在WT而非KO小鼠引起短暂高血糖伴肾上腺素升高;慢性DMPP在WT小鼠改善糖耐量并增加棕色脂肪、心脏和骨骼肌的胰岛素刺激葡萄糖清除,KO小鼠无此获益。
要点
- 急性DMPP在WT小鼠引起短暂高血糖、血浆肾上腺素升高和肝糖原减少,Chrnb4 KO小鼠无此反应。
- 慢性DMPP在WT小鼠连续3天即改善糖耐量,7天时糖耐量明显改善且优于配对喂养小鼠。
- 慢性DMPP增加WT小鼠棕色脂肪(+69%)、心脏(+93%)、腓肠肌(+74%)和股四头肌(+59%)的胰岛素刺激葡萄糖清除。
核心结论
- DMPP急性给药诱导肾上腺素释放和肝糖原分解,慢性给药通过含β4亚基的烟碱型乙酰胆碱受体改善外周胰岛素敏感性,且不依赖体重变化,机制可能涉及骨骼肌非氧化葡萄糖处置增加。
研究设计与样本
- 在饮食诱导肥胖野生型(WT)和Chrnb4敲除(KO)小鼠中,DMPP(10 mg/kg体重,皮下注射)单次给药(急性)或每日给药最长14天(慢性),评估糖耐量、组织特异性示踪剂葡萄糖代谢和胰岛素信号。
主要发现
- 在WT小鼠而非Chrnb4 KO小鼠,单次急性DMPP引起短暂高血糖,伴血浆肾上腺素水平升高、肝脏糖异生基因上调和肝糖原含量降低。
- 慢性DMPP在WT小鼠连续给药3天后即改善糖耐量,7天后糖耐量明显改善,且优于与DMPP处理小鼠配对喂养的小鼠。
- 慢性DMPP的血糖获益在Chrnb4 KO小鼠中缺失。
- 慢性DMPP增加胰岛素刺激的葡萄糖清除进入棕色脂肪(+69%)、心脏(+93%)、腓肠肌(+74%)和股四头肌(+59%),对白色脂肪组织无影响。
- 慢性DMPP处理后,注射DMPP后血浆肾上腺素水平不升高;在葡萄糖刺激的骨骼肌中,糖原合酶抑制性Ser640磷酸化位点磷酸化降低,糖原积累相应增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Treatment with the α3β4 nicotinic acetylcholine receptor (nAChR) agonist, 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), improves glucose tolerance in diet-induced obese (DIO) mice, but the physiological and molecular mechanisms are unknown. METHODS: DMPP (10 mg/kg body weight, s.c.) was administered either in a single injection (acute) or daily for up to 14 days (chronic) in DIO wild-type (WT) and Chrnb4 knockout (KO) mice and glucose tolerance, tissue-specific tracer-based glucose metabolism, and insulin signalling were assessed. RESULTS: In WT mice, but not in Chrnb4 KO mice, single acute treatment with DMPP induced transient hyperglycaemia, which was accompanied by high plasma adrenaline (epinephrine) levels, upregulated hepatic gluconeogenic genes, and decreased hepatic glycogen content. In contrast to these acute effects, chronic DMPP treatment in WT mice elicited improvements in glucose tolerance already evident after three consecutive days of DMPP treatment. After seven days of DMPP treatment, glucose tolerance was markedly improved, also in comparison with mice that were pair-fed to DMPP-treated mice. The glycaemic benefit of chronic DMPP was absent in Chrnb4 KO mice. Chronic DMPP increased insulin-stimulated glucose clearance into brown adipose tissue (+69%), heart (+93%), gastrocnemius muscle (+74%) and quadriceps muscle (+59%), with no effect in white adipose tissues. After chronic DMPP treatment, plasma adrenaline levels did not increase following an injection with DMPP. In glucose-stimulated skeletal muscle, we detected a decreased phosphorylation of the inhibitory Ser640 phosphorylation site on glycogen synthase and a congruent increase in glycogen accumulation following chronic DMPP treatment. CONCLUSIONS/INTERPRETATION: Our data suggest that DMPP acutely induces adrenaline release and hepatic glycogenolysis, while chronic DMPP-mediated activation of β4-containing nAChRs improves peripheral insulin sensitivity independently of changes in body weight via mechanisms that could involve increased non-oxidative glucose disposal into skeletal muscle.
引用
- Jall S, De Angelis M, Lundsgaard AM, et al. Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity. Diabetologia. 2020. PMID: 32140744. doi:10.1007/s00125-020-05117-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。